ABCA1 Genotype

Two people can have nearly identical cholesterol numbers and very different lifetime risks of heart disease. One reason sits in a single gene called ABCA1, which determines how efficiently your cells push cholesterol out and load it onto HDL particles. The variants you inherited at this gene help set your HDL ceiling, your triglyceride baseline, and your susceptibility to atherosclerosis, diabetic dyslipidemia, and possibly Alzheimer's disease.

This test reads the specific DNA letters you carry at ABCA1 (the ATP-binding cassette transporter A1 gene). Unlike cholesterol, the result will be the same in a year, in a decade, and at the end of your life. What changes is how you use it: as a one-time piece of information that reshapes how aggressively you should screen and treat the lipid and cardiometabolic numbers that do move.

What ABCA1 Does

ABCA1 is a cellular pump that moves cholesterol and phospholipids out of cells and onto apolipoprotein A-I (ApoA-I), the protein scaffold that becomes HDL. This is the first step in reverse cholesterol transport, the process by which your body clears excess cholesterol from artery walls and ships it back to the liver. When ABCA1 works well, HDL particles form easily and cholesterol leaves tissue. When it works poorly, HDL stays low and cholesterol lingers.

The ABCA1 gene sits on chromosome 9q31.1, spans 50 exons, and carries thousands of reported variants. Most are common single-letter changes (SNPs) with small effects, a few are rare loss-of-function mutations with large effects, and a smaller number are missense variants that shift transporter function in measurable ways. The test reads the variants on a defined panel, not every possible change in the gene.

Heart Disease and Atherosclerosis Risk

The largest body of evidence ties ABCA1 variants to atherosclerosis and coronary artery disease. A meta-analysis of studies on the common R219K variant found that K-allele carriers had roughly 23% lower atherosclerosis risk than R-allele carriers, with KK carriers showing about 40% lower risk than RR carriers. K-allele carriers also have less severe coronary disease, fewer coronary events, lower triglycerides, and a trend toward higher HDL.

Rare loss-of-function ABCA1 mutations produce a different picture. Carriers can have markedly lower HDL (around 42% below average in one study) and a larger atherosclerotic burden in the carotid arteries, yet a population analysis of 56,886 adults found that heterozygosity for these mutations was not linked to higher ischemic heart disease risk on its own. This is one of several ABCA1 findings that breaks the simple rule that low HDL automatically means high risk.

If you carry a known ABCA1 risk variant, the practical implication is that standard lipid numbers may understate (or in some cases overstate) your cardiovascular risk. Companion testing of ApoB (apolipoprotein B, the particle marker for atherogenic cholesterol), Lp(a), and coronary artery calcium becomes more informative, because they measure the things your inherited HDL biology may be failing to capture.

Why Low HDL From ABCA1 Is Not Always Bad

This is where ABCA1 becomes genuinely counterintuitive. The R230C variant, common in Mexican populations, lowers HDL cholesterol but in one large Mexican cohort was associated with lower premature coronary artery disease risk. The K allele of R219K shows up more often in people with familial hypercholesterolemia who avoid premature heart disease. And the loss-of-function mutation work above showed lower HDL without higher ischemic heart disease risk. ABCA1 is not a 'high HDL good, low HDL bad' marker. It is a genotype that shifts the meaning of HDL itself. Two people with the same HDL value can have very different underlying biology, and the genotype tells you which version you are looking at.

Type 2 Diabetes and Dyslipidemia

ABCA1 variants influence both diabetes risk and the dyslipidemia that often accompanies it. In a study of 330 adults with type 2 diabetes, two specific variants (rs2066714 and rs757194699) were tied to diabetic dyslipidemia, apparently by disrupting how ABCA1 binds to ApoA-I. The R230C variant has complex and population-specific effects on diabetes risk: it is essentially exclusive to people of Native American or Mexican ancestry, and in those populations the original association data actually link it to higher type 2 diabetes risk, likely through its HDL-lowering effect. A separate meta-analysis suggested the C69T variant reduces hypertriglyceridemia risk among people with diabetes.

If you carry a diabetes-modifying ABCA1 variant, the practical move is earlier and more frequent glucose, insulin, and HbA1c (hemoglobin A1c, a measure of average blood sugar over 3 months) monitoring, not waiting for a fasting glucose to drift up in your forties or fifties.

Obesity, Blood Pressure, and Gestational Diabetes

In a study of obese Egyptian children and adolescents, the R219K A allele (the nucleotide change that encodes the K variant) raised both obesity risk and severity, while the I883M G variant was protective. A community-based study of 2,296 Chinese Han adults over 40 linked ABCA1 variants (rs2472510 GG and rs2515614 CC) to higher diastolic blood pressure after standard adjustments. And in 1,757 pregnant women, the R219K variant tracked with diastolic blood pressure, HDL, atherogenic index, and BMI (body mass index) in those with gestational diabetes.

None of these effects are large enough to drive a clinical decision on their own. They matter because they accumulate. An ABCA1 variant that nudges blood pressure, HDL, BMI, and glucose in unfavorable directions across decades adds up to meaningfully higher cardiometabolic risk than any one number suggests.

Alzheimer's Disease Risk

ABCA1 also handles cholesterol movement inside the brain, which is why it shows up in Alzheimer's research. A study of 1,750 participants found that ABCA1 variants modify Alzheimer's risk and influence the cerebrospinal fluid levels of beta-amyloid and tau, the two proteins central to the disease. A meta-analysis identified rs2422493 as associated with higher Alzheimer's risk, with stronger effect in carriers of the APOE-4 (apolipoprotein E type 4) allele. More recently, a 2022 exome sequencing study of more than 32,000 people found that rare damaging variants in ABCA1 were associated with Alzheimer's risk at genome-wide significance, strengthening the link.

A different line of evidence is more nuanced: a study of 671 people found that rare non-synonymous ABCA1 variants were more common in healthy controls than in Alzheimer's cases, suggesting a protective effect from some rare changes. The honest summary is that ABCA1 modifies Alzheimer's risk in ways that depend on the specific variant and on whether you also carry APOE-4. If your ABCA1 result flags an Alzheimer's-associated variant, the actionable step is coordinating with APOE genotyping and aggressive vascular risk reduction, the most evidence-backed lever for dementia prevention available.

Tangier Disease and Severe HDL Deficiency

Two copies of certain rare ABCA1 mutations cause Tangier disease, a condition with near-absent HDL, cholesterol-laden cells, and sometimes neurological symptoms. Whether Tangier disease itself raises premature coronary disease risk is described as controversial in the European Atherosclerosis Society consensus, since the very low LDL that often accompanies it may partly offset the loss of HDL function. ABCA1 genotyping is the definitive test when extremely low HDL and ApoA-I show up on standard labs and the cause is unclear. Cholesterol efflux capacity (a functional test of how well cells push cholesterol onto HDL) is the usual companion measurement. In Tangier homozygotes, efflux to ApoA-I can be completely abolished, which confirms what the genotype suggests.

One Test, Lifelong Result

This is a one-time test. Your ABCA1 genotype was set at conception and will not change. There is no retest schedule, no annual follow-up, no need to confirm next year that the result is still the same. The result lives on, and what changes is how you use it.

What does need ongoing tracking is the lipid and cardiometabolic phenotype that your ABCA1 result helps interpret. If your genotype carries an HDL-lowering or atherosclerosis-risk variant, the recommendation is a baseline advanced lipid panel (including ApoB and Lp(a)) now, repeat in 3 to 6 months if you are starting interventions, and at least annually after that. If your genotype flags diabetes risk, add HbA1c, fasting insulin, and HOMA-IR (homeostasis model assessment of insulin resistance) on the same cadence.

When Genetic Results Can Be Misleading

• Variant panel coverage: this test reads specific known ABCA1 variants on its panel. A 'negative' or 'normal' result does not rule out rare or novel ABCA1 mutations that the panel does not cover. If you have very low HDL and a clinical picture suggesting Tangier disease, ABCA1 sequencing by a different method may be warranted.
• Ancestry-specific allele frequencies: ABCA1 risk variants differ markedly between populations. R230C is essentially exclusive to people of Native American or Mexican ancestry and is rare to absent in others. R219K appears more frequently in Black than White Americans. The clinical meaning of your result depends partly on your ancestry, and lab reports vary in how well they translate this.
• Variants of uncertain significance: ABCA1 has thousands of known variants, and many have unknown clinical effects. If your report flags a variant of uncertain significance, that is exactly what it sounds like, not a hidden warning sign you should act on aggressively.
• Clinical-grade versus consumer testing: a 23andMe-style report may include some ABCA1 markers but typically does not interpret them clinically. A clinical-grade panel is the appropriate source for any decision-making.

What to Do With an Unexpected Result

An out-of-pattern ABCA1 result is not an action by itself. It is a signal to align the rest of your workup. The decision pathway depends on which variant pattern you carry.

If you carry a known atherosclerosis-risk variant (such as the R allele of R219K with other risk factors), the workup includes a full lipid panel with ApoB, Lp(a), and hs-CRP (high-sensitivity C-reactive protein, a marker of vascular inflammation), and consideration of coronary artery calcium imaging in your forties rather than waiting until standard guidelines suggest. If your lipids are well-controlled and ApoB is in range, the genotype changes very little. If your lipids are borderline and ApoB is elevated, the genotype lowers your threshold for starting therapy.

If you carry a known HDL-lowering variant where genetic evidence does not point to higher ischemic heart disease risk (such as the loss-of-function carriers in the Frikke-Schmidt cohort), do not treat your low HDL as a problem to fix in isolation. Focus on the markers that predict your risk, like ApoB and Lp(a). If a Tangier-disease pattern is suggested, the next step is confirmatory sequencing and a cholesterol efflux capacity test, ideally coordinated with a lipidologist.

If you carry an Alzheimer's-associated ABCA1 variant, the most useful companion test is APOE genotyping, because the two interact. A genetic counselor is appropriate before testing if you have significant dementia in the family, and afterward in any case where the result will drive a major change in screening or insurance decisions.